Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : FB-102
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : TD Cowen
Deal Size : $75.0 million
Deal Type : Public Offering
Forte Biosciences Announces Pricing of $75 Million Public Offering
Details : The proceeds from the offering will be used to fund the clinical development of FB-102, which is being evaluated for the treatment of celiac disease.
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
June 25, 2025
Lead Product(s) : FB-102
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : TD Cowen
Deal Size : $75.0 million
Deal Type : Public Offering
Lead Product(s) : FB102
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Non-segmental Vitiligo
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 02, 2025
Lead Product(s) : FB102
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : FB-102
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Sponsor : OrbiMed Advisors
Deal Size : $53.0 million
Deal Type : Private Placement
Forte Biosciences Raises $53M to Advance FB102 in Autoimmune Disorders
Details : The proceeds will support the clinical advancement of FB102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications.
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
November 20, 2024
Lead Product(s) : FB-102
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Sponsor : OrbiMed Advisors
Deal Size : $53.0 million
Deal Type : Private Placement
Lead Product(s) : FB-102
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Alger
Deal Size : $25.0 million
Deal Type : Financing
Forte Biosciences, Inc. Announces $25 Million Financing and R&D Update for FB-102
Details : The net financing will support the advancement of FB-102, which targets CD-122 and has demonstrated potentially best in class activity in graft versus host disease (GvHD).
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
January 08, 2023
Lead Product(s) : FB-102
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Alger
Deal Size : $25.0 million
Deal Type : Financing
Lead Product(s) : FB-401
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Inapplicable
June 23, 2021
Lead Product(s) : FB-401
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : FB-401
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Phase 2 clinical trial of FB-401 for the treatment of atopic dermatitis failed to meet statistical significance for the primary endpoint of EASI-50 (the proportion of patients with at least a 50% improvement in atopic dermatitis disease severity as measu...
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Inapplicable
February 09, 2021
Lead Product(s) : FB-401
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : FB-401
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The primary endpoint of EASI-50 was achieved by 58% of subjects on FB-401 compared to 60% of subjects on placebo. Positive trends were observed in key secondary endpoints including EASI-90 with 27.6% of subjects in the active arm achieving the EASI-90 en...
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Inapplicable
February 09, 2021
Lead Product(s) : FB-401
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : FB-401
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : FB-401 is a topically applied live biotherapeutic consisting of specifically selected strains of commensal Roseomonas mucosa and has demonstrated excellent tolerability and significant improvement in atopic dermatitis disease activity in both adults and ...
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Inapplicable
October 26, 2020
Lead Product(s) : FB-401
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : FB-401
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The multi-center, placebo controlled clinical trial of FB-401 is expected to enroll approximately 124 pediatric, adolescent and adult subjects aged 2 years of age and older with atopic dermatitis (AD).
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Inapplicable
September 29, 2020
Lead Product(s) : FB-401
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : FB-401
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Inapplicable
August 07, 2020
Lead Product(s) : FB-401
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable